# EDGAR Filing Document

**Accession Number:** 0001659617
**File Stem:** 0001437749-26-003119
**Filing Date:** 2026-2
**Character Count:** 6448
**Document Hash:** a17abc4ff907eba2d70d595ce622cc0e
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001437749-26-003119.hdr.sgml**: 20260205

**ACCESSION NUMBER**: 0001437749-26-003119

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20260205

**ITEM INFORMATION**: Submission of Matters to a Vote of Security Holders

**FILED AS OF DATE**: 20260205

**DATE AS OF CHANGE**: 20260205

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Moleculin Biotech, Inc.
- **CENTRAL INDEX KEY:** 0001659617
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 474671997
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-37758
- **FILM NUMBER:** 26601411

**BUSINESS ADDRESS:**
- **STREET 1:** 5300 MEMORIAL DRIVE
- **STREET 2:** SUITE 950
- **CITY:** HOUSTON
- **STATE:** TX
- **ZIP:** 77007
- **BUSINESS PHONE:** 713-300-5160

**MAIL ADDRESS:**
- **STREET 1:** 5300 MEMORIAL DRIVE
- **STREET 2:** SUITE 950
- **CITY:** HOUSTON
- **STATE:** TX
- **ZIP:** 77007

?xml version='1.0' encoding='ASCII'? mbrx20260204_8k.htm

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934**

**DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): February 5, 2026**

![logobig.jpg](logobig.jpg)

**MOLECULIN BIOTECH, INC.**

(Exact Name of Registrant as Specified in its Charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-37758** | **47-4671997** |
| (State or Other Jurisdiction of Incorporation or Organization) | (Commission File No.) | (I.R.S. Employer Identification No.) |

---

**5300 Memorial Drive, Suite 950, Houston ,TX 77007**

(Address of principal executive offices and zip code)

&nbsp;&nbsp;&nbsp;&nbsp;**(713) 300-5160**

(Registrant's telephone number, including area code)

(Former name or former address, if changed from last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-14(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol (s)** | **Name of each exchange on which registered** |
| Common Stock, par value $.001 per share | MBRX | The NASDAQ Stock Market LLC |

---

------

**Item 5.07 Submission of Matters to a Vote of Security Holders.**

On February 5, 2026, the Company held a Special Meeting of Stockholders (the "Special Meeting"). As of December 11, 2025, the record date for the Special Meeting, there were 2,693,531 shares of common stock issued and outstanding and entitled to vote on the proposals presented at the Special Meeting, of which 1,196,312 shares were present in person or represented by proxy, which constituted a quorum. The holders of shares of our common stock are entitled to one vote for each share held. Set forth below are the final voting results for each of the proposals submitted to a vote of the Company's stockholders at the Special Meeting. Each of these proposals is described in greater detail in the Company's definitive proxy statement filed with the Securities and Exchange Commission on January 2, 2026 (the "Proxy Statement").

**Proposal 1. Approve the Nasdaq Proposal for Certain Warrants Issued on December 11, 2025** - The Company's stockholders approved the issuance of up to 2,610,823 shares of Company common stock upon the exercise of certain warrants issued on December 11, 2025, by the following vote:

---

| | | | |
|:---|:---|:---|:---|
| **Votes For** | **Votes Against** | **Abstain** | **Broker Non-Votes** |
| 578,385 | 68,176  | 3,444  | 546,307  |

---

**Proposal 2. Approve an Amendment to Change the Company**'**s Name from Moleculin Biotech, Inc. to Moleculin Inc. -** The Company's stockholders did not approve an amendment to the Company's Amended and Restated Certificate of Incorporation, as amended, to change the Company's name from Moleculin Biotech, Inc. to Moleculin Inc. (as such vote required a majority of the outstanding shares on the record date to vote "For" which did not occur) by the following vote:

---

| | | | |
|:---|:---|:---|:---|
| **Votes For** | **Votes Against** | **Abstain** | **Broker Non-Votes** |
| 1,124,921 | 67,441  | 3,950 | N/A  |

---

**Proposal 3. Approve an Adjournment -** The Company's stockholders approved an adjournment, if necessary, to solicit additional proxies if there are not sufficient votes in favor of the Nasdaq Proposal or the Name Change Proposal, by the following vote:

---

| | | | |
|:---|:---|:---|:---|
| **Votes For** | **Votes Against** | **Abstain** | **Broker Non-Votes** |
| 582534 | 64190 | 3281 | 546,307  |

---

**<u>SIGNATURE</u>**

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| |
|:---|
| **MOLECULIN BIOTECH, INC.** |
| Date: February 5, 2026<br> By: <u>/s/ Jonathan P. Foster</u><br> Jonathan P. Foster<br> Chief Financial Officer |

---